As previously discussed, TMPRSS2/ERG rearrangement is present in about half of prostate tumors [53] and is associated with distinct clinicopathological features, including younger age at diagnosis, higher Gleason score, and more aggressive disease behavior, highlighting its potential prognostic significance as ERG fusions are prevalent in both primary and advanced PCa. Here, TMPRSS2 is linked to prostate neoplasm.